In the first quarter of 2026, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests, including:

• 13ACT | Coagulation Factor XIII (13) Activity Assay, Plasma
  • Measuring factor XIII activity.
  • Congenital FXIII deficiency is an autosomal recessive bleeding disorder.
• AHPV | Anal Pap Human Papillomavirus (HPV) with Genotyping, High-Risk Types, PCR, Varies
  • Detection of high-risk (HR) genotypes associated with the development of anal cancer.
  • Individual genotyping of human papillomavirus (HPV)-16 and HPV-18, if present.
  • May aid in triaging men and women with positive HR HPV but negative anal Papanicolaou (Pap) smear test results.
  • This test is not intended for use in medical-legal applications.
• APLDF | Acute Promyelocytic Leukemia-PML: RARA fusion, Expedited Diagnostic FISH, Varies
  • Detecting, at diagnosis, acute promyelocytic leukemia (APL).
  • This test should not be used to screen for residual APL.
  • Test results are finalized and released seven days a week. All attempts will be made to provide final results the day of specimen receipt at Mayo Clinic Laboratories. Some results may not be reported until the following day due to established cutoff times or if additional RARA testing is required.
• HSCHP | High Sensitivity Clonal Hematopoiesis Panel
  • Evaluating clonal hematopoiesis (CH) prior to initiation of genotoxic therapy.
  • Monitoring clonal evolution and the emergence of clinically relevant clones throughout the course of genotoxic treatment.
  • Distinguishing tumor driver mutations from CH-associated variants.
• MIRI | Mirikizumab, Serum
  • Assessing the response to mirikizumab therapy.
  • Assessing the need for dose escalation.
  • Evaluating the potential for dose de-escalation or discontinuation of therapy.
  • Monitoring patients who need to be above a certain mirikizumab concentration to improve the odds of a clinical response for therapy optimization.
• SORDB | Sorbitol & Xylitol, Quantitative, Whole Blood
  • Screening and treatment monitoring for sorbitol dehydrogenase deficiency-related neuropathy.

• URNS | Bacterial Culture, Aerobic, with Antimicrobial Susceptibilities, Urine
  • Diagnosing urinary tract infections.
  • May be helpful in discriminating contamination, colonization, and infection.
  • Determining the in vitro antimicrobial susceptibility of potentially pathogenic aerobic bacteria, if appropriate.
  • This test is not intended for medicolegal use.

Visit our test catalog for more information on new or updated tests and testing algorithms.